Drug Trial Radar · NCT05549505
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Last checked: Nov 19, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
152
Actual
Start
Feb 15, 2023
Primary completion
Jul 13, 2024
Study completion Jul 25, 2024
Sponsor
- Lead sponsor
- Arvinas Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Sep 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with estrogen receptor positive/ human epidermal growth factor receptor 2 (ER+/HER2)- localized breast cancer.
Conditions
- Breast Cancer
Interventions
ARV-471Drug
100 mg tablet
AnastrozoleDrug
1 mg tablet
Surgical resection of breast tumorProcedure
Surgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Reduction in Ki-67 Expression From Baseline to Day 15 in Tumor BiopsiesTime frame: Baseline (during screening, prior to Day 1) and Day 15
Locations
49 sites in 4 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Springdale, Arkansas
Clinical Trial Site
Los Angeles, California
Clinical Trial Site
Torrance, California
Clinical Trial Site
Van Nuys, California
Clinical Trial Site
Fort Lauderdale, Florida
Clinical Trial Site
Fort Myers, Florida
Clinical Trial Site
Orlando, Florida
Clinical Trial Site
West Palm Beach, Florida
Clinical Trial Site
Iowa City, Iowa
Clinical Trial Site
Springfield, Massachusetts
Clinical Trial Site
St Louis, Missouri
Clinical Trial Site
Nashville, Tennessee
Clinical Trial Site
Tacoma, Washington
Clinical Trial Site
Batumi, Georgia
Clinical Trial Site
Tbilisi, Georgia
Clinical Trial Site
Tbilisi, Georgia
Clinical Trial Site
Tbilisi, Georgia
Clinical Trial Site
Augsburg, Germany
Clinical Trial Site
Berlin, Germany
Clinical Trial Site
Bonn, Germany
Clinical Trial Site
Bottrop, Germany
Clinical Trial Site
Chemnitz, Germany
Clinical Trial Site
Dresden, Germany
Clinical Trial Site
Erlangen, Germany
Clinical Trial Site
Essen, Germany
Clinical Trial Site
Essen, Germany
Clinical Trial Site
Esslingen am Neckar, Germany
Clinical Trial Site
Mannheim, Germany
Clinical Trial Site
Paderborn, Germany
Clinical Trial Site
Alicante, Spain
Clinical Trial Site
Barcelona, Spain
Clinical Trial Site
Barcelona, Spain
Clinical Trial Site
Barcelona, Spain
Clinical Trial Site
Castelló, Spain
Clinical Trial Site
Córdoba, Spain
Clinical Trial Site
Granada, Spain
Clinical Trial Site
Granada, Spain
Clinical Trial Site
Lleida, Spain
Clinical Trial Site
Madrid, Spain
Clinical Trial Site
Madrid, Spain
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.